Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Monolithic Power Systems Inc (MPWR) Price & Performance

AbbVie IncTrade
Monolithic Power Systems IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Monolithic Power Systems Inc — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Monolithic Power Systems Inc trades at $1,419.98 (market cap $67.87B). The key difference: AbbVie Inc is far larger — about 6.5× Monolithic Power Systems Inc's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.

ABBVMPWR
Market Cap
$438.19B$67.87B
Sector
HealthUtilities
52-Week High
$263.58$1.69K
52-Week Low
$197.38$820.74
Enterprise Value
$502.45B$66.48B
Dividend Yield
2.79%0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Monolithic Power Systems Inc

Monolithic Power Systems (MPWR) trades at $1,401.54, up 3.12% today, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, supported by robust fundamentals including 24.5% net income margin and 21.98% ROE. Recent Q2 2026 results showed EPS of $6.50, exceeding estimates, with revenue growth driven by AI infrastructure demand. Analyst sentiment remains overwhelmingly positive with 88% buy ratings.

The outlook for MPWR is favorable due to accelerating AI-driven revenue and expanding margins, though high valuation multiples (P/E 84.26) pose a risk if growth slows. Investor optimism is tempered by potential overvaluation and sensitivity to tech sector volatility. The consensus price target of $1,870 suggests upside, but execution risks and competitive pressures warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR